Several weeks ago cardiologists representing 72 organizations from all over the world announced that a new drug called tirofiban -- also known as aggrastat -- could reduce the risk of death in unstable angina patients by 47%. The drug attaches to and blocks biochemical doorways on platelet cells called IIb/IIIa receptors. When bound to these receptors, the drug keeps fibrinogen -- a protein found in the blood -- from adhering to platelets, thereby preventing the formation of platelet thrombi, which can cause arterial blockage.
The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.
Cite This Page: